Sagimet director sells 350,987 shares after option exercise
Sagimet Biosciences Inc. director George Kemble reported option exercises and a share sale in Series A Common Stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Sagimet Biosciences Inc. director George Kemble reported option exercises and a share sale in Series A Common Stock. On August 14, 2026, he exercised stock options covering 326,618 and 24,369 shares at an exercise price of $6.36 per share, receiving the same number of Series A Common shares. That same day, he sold 350,987 Series A Common shares at a weighted average price of $10.2328 per share, in multiple trades between $9.95 and $10.57. These transactions were conducted under a Rule 10b5-1 trading plan adopted on August 21, 2025, and the option was fully vested and exercisable as of the transaction date.
Insider Trade Summary 10b5-1
Exercise and Sale: 350,987 shares ($1.36M approx. pre-tax spread)
Exercise and Sale
5 txns
Insider
Kemble George
Role
Director
Sold
350,987 shs ($3.59M)
Approx. gross sale proceeds
$3.59M
Approx. exercise cost
$2.23M
Approx. pre-tax spread
$1.36M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F3 | 326,618 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) F1, F3 | 24,369 | $0.00 | $0.00 |
| Exercise | Series A Common Stock F1 | 326,618 | $6.36 | $2.08M |
| Exercise | Series A Common Stock F1 | 24,369 | $6.36 | $155K |
| Sale | Series A Common Stock F1, F2 | 350,987 | $10.2328 | $3.59M |
Holdings After Transaction:
Stock Option (Right to Buy) — 43,063 contracts (Direct);
Series A Common Stock — 62,161 shares (Direct)
Footnotes (3)
- F1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.95 to $10.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3. This option is fully vested and exercisable as of the date hereof.
Key Figures
Options Exercised - Tranche 1: 326,618 shares
Options Exercised - Tranche 2: 24,369 shares
Option Exercise Price: $6.36 per share
+4 more
7 metrics
Options Exercised - Tranche 1
326,618 shares
Stock Option (Right to Buy) exercised into Series A Common Stock on August 14, 2026
Options Exercised - Tranche 2
24,369 shares
Stock Option (Right to Buy) exercised into Series A Common Stock on August 14, 2026
Option Exercise Price
$6.36 per share
Conversion or exercise price of stock options into Series A Common Stock
Shares Sold
350,987 shares
Series A Common Stock sold on August 14, 2026
Weighted Average Sale Price
$10.2328 per share
Weighted average price for Series A Common shares sold, with trades from $9.95 to $10.57
Rule 10b5-1 Plan Adoption Date
August 21, 2025
Date the trading plan governing these transactions was adopted
Option Expiration Date
April 27, 2029
Expiration date of the exercised stock options
Key Terms
Rule 10b5-1 trading plan, weighted average price, Series A Common Stock, Stock Option (Right to Buy)
4 terms
Rule 10b5-1 trading plan regulatory
"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Series A Common Stock financial
"underlying_security_title": "Series A Common Stock""
Series A common stock is a specific class of a company’s ordinary shares issued during an early formal funding round, carrying the ownership rights and voting power tied to that class. For investors it signals an early-stage equity claim with potential upside if the business grows, but also greater risk and typically less liquidity than shares in mature, publicly traded firms—imagine buying a seat on a startup’s team before the company has proven itself.
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Sagimet Biosciences (SGMT) report for George Kemble?
George Kemble exercised stock options and sold 350,987 Sagimet Biosciences Series A Common shares. The transactions on August 14, 2026 involved exercising options at $6.36 per share and selling shares at a weighted average price of $10.2328 under a Rule 10b5-1 plan.
How many Sagimet Biosciences (SGMT) options did George Kemble exercise and at what price?
He exercised options for 326,618 and 24,369 shares of Sagimet Series A Common. Each option had an exercise price of $6.36 per share, and the option was fully vested and exercisable as of the transaction date.
What type of security did George Kemble exercise into Sagimet Biosciences (SGMT) stock?
He exercised Stock Option (Right to Buy) awards into Sagimet Series A Common Stock. The options, fully vested as of the date of exercise, converted into the same number of Series A Common shares at an exercise price of $6.36 per share.
AI-generated analysis. How Rhea-AI works. Not financial advice.
